Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Pulmonology

Standard of Care Treatment: Biologics and GINA Guidelines

At a Glance

Biologics for severe eosinophilic asthma target the specific inflammatory proteins causing your symptoms. A primary goal of these treatments, following GINA guidelines, is to reduce asthma attacks and help you safely taper off harmful oral steroids like prednisone.

When standard inhalers aren’t enough, the Global Initiative for Asthma (GINA) guidelines provide a clear roadmap for what comes next. For patients with severe Type 2 asthma, the focus shifts from just “opening the airways” to targeting the specific biological “alarm bells” that cause inflammation. [1][2]

The Goal: Steroid Stewardship

The “North Star” of modern severe asthma treatment is to reduce or eliminate the need for oral corticosteroids (OCS) like prednisone. [3] While OCS can stop an attack, their long-term use is harmful. Biologics are designed to take over the heavy lifting, allowing you to taper off steroids safely under medical supervision. [4][5]

The Biologic “Toolbox”

Biologics are advanced medications—usually given by injection—that target specific proteins in your immune system. Doctors use your blood tests (eosinophils) and breath tests (FeNO) to choose the right “tool” for your specific asthma phenotype (your specific observable type of asthma). [6][7]

1. The Eosinophil Blockers (Anti-IL-5)

These medications target the “recruitment signal” (IL-5) that brings eosinophils into your lungs. [8]

  • Mepolizumab and Reslizumab: These bind directly to the IL-5 protein to “neutralize” it before it can activate your eosinophils. [9][10]
  • Benralizumab: This takes a more direct approach by attaching to the receptor on the eosinophil itself, signaling your immune system to clear those cells away. [11][12]

2. The Multi-Pathway Blocker (Anti-IL-4/IL-13)

  • Dupilumab: Instead of targeting eosinophils directly, this medication blocks the receptors for two different proteins (IL-4 and IL-13) that drive mucus production and airway scarring. [13] It is particularly effective if you also have nasal polyps or eczema. [14]

3. The “Upstream” Blocker (Anti-TSLP)

  • Tezepelumab: This is the newest type of biologic. It targets a protein called TSLP, which sits “upstream” at the very beginning of the inflammatory cascade. [15] Because it stops the alarm before it spreads, it can work for a broader range of patients, including those whose eosinophil levels aren’t very high. [16][17]

4. The Allergic Blocker (Anti-IgE)

  • Omalizumab: While primarily used for allergic asthma, many patients with severe eosinophilic asthma have an overlapping allergic phenotype. This biologic blocks the allergic antibodies (IgE) that trigger inflammation. [18]

Administration: It’s worth noting that after initial training, several of these biologics (such as dupilumab, mepolizumab, and benralizumab) can eventually be self-administered at home via an auto-injector, offering a massive quality-of-life benefit. [19]

What to Expect: Notable Side Effects

While biologics are generally well-tolerated and often safer for the whole body than long-term prednisone, they do have specific side effects to monitor: [4]

  • Injection Site Reactions: Redness, swelling, or itching at the spot where the shot was given is the most common side effect for all biologics. [20]
  • Conjunctivitis (Pink Eye): This is a unique side effect specifically associated with dupilumab. It can cause itchy, red, or watery eyes. Most cases are mild and can be managed with eye drops without stopping the medication. [21][22]
  • Transient Eosinophilia: In some patients, dupilumab can cause a temporary spike in blood eosinophil levels as they are pushed out of the tissues and into the bloodstream. Your doctor will monitor your blood work to ensure these levels settle down. [23][20]
  • Rare Hypersensitivity: As with any medication, there is a very small risk of a serious allergic reaction. Most clinics will have you wait for 20-30 minutes after your first few doses to ensure you are safe. [20][24]

When Will It Work?

Biologics are not “rescue” inhalers; they don’t work instantly. It can take 3 to 6 months of consistent treatment to determine if a specific biologic is working for you. [25] Success is measured by having fewer attacks, better breathing, and—most importantly—needing less prednisone. [26][27]

Common questions in this guide

How does my doctor decide which asthma biologic is best for me?
The right biologic depends on your specific asthma profile, known as your phenotype. Doctors use your blood eosinophil count and a FeNO breath test to choose an anti-IL-5, anti-IL-4/IL-13, anti-TSLP, or anti-IgE biologic that best targets your inflammation.
Can asthma biologics help me get off prednisone?
Yes, a major goal of biologic therapy is to reduce or eliminate the need for oral corticosteroids like prednisone. Biologics control the underlying inflammation, allowing your doctor to help you taper off steroids safely.
How long does it take for an asthma biologic to start working?
Biologics are not rescue inhalers and do not provide instant relief. It typically takes 3 to 6 months of consistent treatment to determine if the medication is successfully reducing your attacks and improving your breathing.
Is pink eye a common side effect of asthma biologics?
Conjunctivitis, or pink eye, is a specific side effect associated with dupilumab. It can cause itchy, red, or watery eyes, but most cases are mild and can usually be managed with eye drops without stopping the biologic.
Do I have to go to the clinic for every biologic injection?
Many asthma biologics can be taken at home. After you receive initial training at your doctor's office, medications like dupilumab, mepolizumab, and benralizumab can be self-administered using an auto-injector pen.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my eosinophil count and FeNO levels, which specific biologic medication do the GINA guidelines recommend for me?
  2. 2.What is our specific timeline and protocol for tapering my oral steroids once I start a biologic?
  3. 3.If I start dupilumab, what symptoms of conjunctivitis should I watch for, and do you recommend a baseline eye exam?
  4. 4.How long should we try a specific biologic before we decide if it's working or if we should switch to a different target (like moving from anti-IL-5 to anti-TSLP)?
  5. 5.Does my history of [eczema/nasal polyps/sinusitis] make one biologic a better choice for me than the others?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Wildfire Smoke Stop Asthma Biologics from Working?Do Fasenra or Nucala Protect Against Wildfire Smoke?What If Your Rescue Inhaler Fails During Wildfire Smoke?Why Does Wildfire Smoke Cause a Delayed Asthma Flare-Up?

References

References (27)
  1. 1

    Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion.

    Buhl R, Bel E, Bourdin A, et al.

    The journal of allergy and clinical immunology. In practice 2022; (10(2)):422-432 doi:10.1016/j.jaip.2021.10.059.

    PMID: 34763123
  2. 2

    Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction.

    Ramphul M, Lo DKH, Gaillard EA

    Journal of asthma and allergy 2021; (14()):525-538 doi:10.2147/JAA.S265657.

    PMID: 34045872
  3. 3

    [Biologics for the treatment of severe asthma: Current status report 2023].

    Paçacı Çetin G, Kepil Özdemir S, Can Bostan Ö, et al.

    Tuberkuloz ve toraks 2023; (71(2)):176-187 doi:10.5578/tt.20239921.

    PMID: 37345400
  4. 4

    Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.

    Agache I, Beltran J, Akdis C, et al.

    Allergy 2020; (75(5)):1023-1042 doi:10.1111/all.14221.

    PMID: 32034960
  5. 5

    Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.

    Lugogo N, Domingo C, Chanez P, et al.

    Clinical therapeutics 2016; (38(9)):2058-2070.e1.

    PMID: 27553751
  6. 6

    Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis.

    Canonica GW, Blasi F, Crimi N, et al.

    Clinical and molecular allergy : CMA 2021; (19(1)):5 doi:10.1186/s12948-021-00146-9.

    PMID: 34020658
  7. 7

    Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics.

    Bourdin A, Brusselle G, Couillard S, et al.

    The journal of allergy and clinical immunology. In practice 2024; (12(4)):809-823 doi:10.1016/j.jaip.2024.01.023.

    PMID: 38280454
  8. 8

    Mepolizumab as Possible Treatment for Allergic Bronchopulmonary Aspergillosis: A Review of Eight Cases.

    Tolebeyan A, Mohammadi O, Vaezi Z, Amini A

    Cureus 2020; (12(8)):e9684 doi:10.7759/cureus.9684.

    PMID: 32923277
  9. 9

    Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab.

    Calzetta L, Ritondo BL, Matera MG, et al.

    British journal of pharmacology 2020; (177(20)):4750-4765 doi:10.1111/bph.15240.

    PMID: 32857420
  10. 10

    Role of biologics in severe eosinophilic asthma - focus on reslizumab.

    Pelaia G, Vatrella A, Busceti MT, et al.

    Therapeutics and clinical risk management 2016; (12()):1075-82 doi:10.2147/TCRM.S111862.

    PMID: 27445482
  11. 11

    Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.

    Bleecker ER, FitzGerald JM, Chanez P, et al.

    Lancet (London, England) 2016; (388(10056)):2115-2127 doi:10.1016/S0140-6736(16)31324-1.

    PMID: 27609408
  12. 12

    Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.

    Hillas G, Fouka E, Papaioannou AI

    Expert review of respiratory medicine 2020; (14(4)):353-365 doi:10.1080/17476348.2020.1718495.

    PMID: 31958239
  13. 13

    Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.

    Olaguibel JM, Sastre J, Rodríguez JM, Del Pozo V

    Journal of investigational allergology & clinical immunology 2022; (32(3)):165-180 doi:10.18176/jiaci.0823.

    PMID: 35522053
  14. 14

    Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.

    Rabe KF, Nair P, Brusselle G, et al.

    The New England journal of medicine 2018; (378(26)):2475-2485 doi:10.1056/NEJMoa1804093.

    PMID: 29782224
  15. 15

    Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.

    Panettieri R, Lugogo N, Corren J, Ambrose CS

    Journal of asthma and allergy 2024; (17()):219-236 doi:10.2147/JAA.S342391.

    PMID: 38524099
  16. 16

    Real-world evidence of tezepelumab for severe asthma: a retrospective multicentre cohort.

    Khateeb J, Kramer MR, Freund O, et al.

    ERJ open research 2025; (11(5)) doi:10.1183/23120541.00314-2025.

    PMID: 40901376
  17. 17

    NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.

    Menzies-Gow A, Colice G, Griffiths JM, et al.

    Respiratory research 2020; (21(1)):266 doi:10.1186/s12931-020-01526-6.

    PMID: 33050934
  18. 18

    Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS).

    Pera V, Brusselle GG, Riemann S, et al.

    Frontiers in pharmacology 2023; (14()):1276340 doi:10.3389/fphar.2023.1276340.

    PMID: 38035014
  19. 19

    A review of the safety of antibody therapy in severe eosinophilic asthma.

    Matera MG, De Novellis V, Rogliani P, Cazzola M

    Expert review of respiratory medicine 2026; (20(6)):673-692 doi:10.1080/17476348.2025.2607151.

    PMID: 41412959
  20. 20

    Dupilumab side effect in a patient with atopic dermatitis: a case report study.

    Albader SS, Alharbi AA, Alenezi RF, Alsaif FM

    Biologics : targets & therapy 2019; (13()):79-82 doi:10.2147/BTT.S195512.

    PMID: 31190731
  21. 21

    Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment.

    Asbell P, Akpek E, Chamberlain W, et al.

    Advances in therapy 2025; (42(7)):3285-3305 doi:10.1007/s12325-025-03209-4.

    PMID: 40388089
  22. 22

    Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis.

    Maudinet A, Law-Koune S, Duretz C, et al.

    Ophthalmology and therapy 2019; (8(3)):485-490 doi:10.1007/s40123-019-0191-9.

    PMID: 31230264
  23. 23

    Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting.

    Li SH, Nehme KF, Moshkovich A, et al.

    The journal of allergy and clinical immunology. In practice 2025; (13(1)):121-131 doi:10.1016/j.jaip.2024.09.013.

    PMID: 39322036
  24. 24

    A rare case of keloid combined with bullous pemphigoid.

    Zhang Y, Gong Y, Shi X, et al.

    Dermatology reports 2025; doi:10.4081/dr.2025.10484.

    PMID: 41069272
  25. 25

    Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype.

    Rabe KF, FitzGerald JM, Bateman ED, et al.

    The journal of allergy and clinical immunology. In practice 2022; (10(11)):2916-2924.e4 doi:10.1016/j.jaip.2022.06.036.

    PMID: 36028446
  26. 26

    Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register.

    Soendergaard MB, Hansen S, Bjerrum AS, et al.

    ERJ open research 2022; (8(4)) doi:10.1183/23120541.00238-2022.

    PMID: 36199589
  27. 27

    Effectiveness of Mepolizumab in Patients with OCS-Dependent Severe Asthma: A Real-World Study.

    Bavbek S, Al-Ahmad M, Samaha H, et al.

    Advances in therapy 2025; (42(11)):5481-5498 doi:10.1007/s12325-025-03338-w.

    PMID: 40879894

This page explains standard biologic treatments for severe eosinophilic asthma for educational purposes only. Always consult your pulmonologist or allergist before changing your asthma medication plan or tapering steroids.

Get notified when new evidence is published on Severe Refractory Eosinophilic Asthma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.